Detection of Viruses By Counting Single Fluorescent Genetically Biotinylated Reporter Immunophage Using a Lateral Flow Assay by Kim, Jinsu et al.
Detection of Viruses By Counting Single Fluorescent Genetically 
Biotinylated Reporter Immunophage Using a Lateral Flow Assay
Jinsu Kim1, Meena Adhikari2, Sagar Dhamane2, Anna E. V. Hagström1, Katerina 
Kourentzi1, Ulrich Strych3, Richard C. Willson1,2,4,5,*, and Jacinta C. Conrad1,*
1Chemical and Biomolecular Engineering, University of Houston, Houston, TX, 77204 USA
2Biology and Biochemistry, University of Houston, Houston, TX, 77204 USA
3Section of Pediatric Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA
4Houston Methodist Research Institute, Houston, TX, 77030, USA
5Tecnológico de Monterrey, Departamento de Biotecnología e Ingeniería de Alimentos, Centro de 
Biotecnología FEMSA, Monterrey, Nuevo León, Mexico
Abstract
We demonstrated a lateral flow immunoassay (LFA) for detection of viruses using fluorescently-
labeled M13 bacteriophage as reporters and single-reporter counting as the readout. AviTag-
biotinylated M13 phage were functionalized with antibodies using avidin-biotin conjugation and 
fluorescently labeled with AlexaFluor 555. Individual phage bound to target viruses (here MS2 as 
a model) captured on an LFA membrane strip were imaged using epi-fluorescence microscopy. 
Using automated image processing, we counted the number of bound phage in micrographs as a 
function of target concentration. The resultant assay was more sensitive than enzyme-linked 
immunosorbent assays and traditional colloidal-gold nanoparticle LFAs for direct detection of 
viruses.
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Introduction
Reducing infection and mortality rates from viral pathogens, such as dengue1 and Ebola 
viruses2, requires rapid and early diagnosis. This need poses a special challenge in 
economically challenged areas with limited laboratory infrastructure where these viruses are 
often endemic. Early diagnosis under these conditions is aided by point-of-care (POC) 
diagnostics3 that are able to detect viruses at low concentrations and without involved 
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sample preparation. Traditional techniques for detecting viruses, including plaque assays 
and polymerase chain reaction (PCR),4–5 often require complex laboratory equipment and 
trained personnel and are therefore poorly suited for early diagnosis in these settings.
Lateral flow assays (LFAs) are a rapid, cheap, and simple option for POC diagnosis.6 In a 
typical LFA format, a biological sample containing an analyte is dispensed onto the sample 
pad of a porous membrane strip and transported through it by capillary action; antibodies 
bound to the membrane capture the analytes as they flow through the strip. Reporter 
particles also transported by the flow are then analyte-bridged and arrested by antibodies at 
the test line to produce an easily discernible line on the strip as a positive result. LFAs using 
gold, dyed latex, or carbon nanoparticles as reporters require minimal sample preparation 
and hence are routinely used in research and clinical applications.7 Traditional nanoparticle-
based LFAs6–8, however, typically cannot detect viral antigens at concentrations in 
clinically-useful ranges (e.g. 103—106 viral particles per mL for HIV-19, 101—106 plaque 
forming units per mL for Ebola10, and 101—104 plaque forming units per mL for dengue11) 
due to limited readout; for example, colloidal gold LFAs for Japanese encephalitis virus can 
detect viruses at a concentration of 2.5 × 106 pfu/mL12 and filamentous Escherichia coli 
M13 bacteriophage (phage) at a concentration of 5 × 107 pfu/mL.13 By contrast, complex 
laboratory methods such as plaque counting and polymerase chain reaction have much lower 
limits of detection.4–5 For LFAs to be most useful as early diagnostics for viral diseases, 
new reporter technologies are needed with increased sensitivity and decreased limits of 
detection.
An intriguing alternative to the nanoparticles conventionally used as LFA reporters are viral 
nanoparticles, such as bacteriophage. Phage surfaces can be genetically and chemically 
engineered to display a wide range of functional groups, including antibodies, aptamers, 
lectins, peptides, proteins, and enzymes,14–15 enabling recognition and readout. This 
property allows engineered phage to serve as universal biodetection reporters in diagnostic 
assays,16–19 including enzyme-linked immunosorbent assays (ELISAs)20–23 and 
colorimetric LFAs.24 In addition, phage bearing fluorescent moieties have been employed in 
a variety of biodetection assays that use flow cytometry25–29 or fluorescence 
microscopy27, 30–31 as readouts. Such fluorescently-labeled phage are of particular interest 
for use in LFAs, as many phage (e.g. M13, T7) are large enough to be imaged using optical 
microscopy as diffraction-limited objects when labeled with fluorescent dyes32–33 and hence 
can be singly counted using automated image-processing routines.34 We therefore posited 
that the combination of coat protein engineering and fluorescence could enable a new LFA 
readout, in which phage reporters bound to analytes are singly counted, that may increase 
LFA sensitivity.
Here, we report a lateral-flow immunoassay based on enumerating individual fluorescently 
labeled bacteriophage reporters. We first developed a protocol to fluorescently label the p8 
major coat proteins of M13, and then functionalized the p3 tail protein displaying a 
biotinylatable AviTag peptide with antibodies to MS2, a widely used model for viral 
pathogens. At each step in the protocol we confirmed that reporters were successfully 
modified using ELISA, 4′-hydroxyazobenzene-2-carboxylic acid (HABA) assay, and a 
magnetic particle counting assay. In the LFA, Fusion 5 membranes were functionalized with 
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test and control lines that contain antibodies to MS2 and to the M13 reporter, respectively, 
as shown in Figure 1. Defined numbers of MS2 phage were flowed through the LFA matrix 
and captured at the test line, which contained anti-MS2 antibodies. Fluorescent M13 
reporters functionalized with anti-MS2 antibodies subsequently flowed through the strip 
were captured by the MS2 on the test line and by anti-M13 antibodies on the control line. 
We acquired fluorescence micrographs at the test, transition, and control lines and used 
automated image-processing algorithms to count the number of reporter phage at each 
location at the single-label level. The limit of detection (LoD) of this assay, determined from 
the 95% confidence intervals on the number of counted M13 reporters, is 102 plaque-
forming units (pfu) in a 10 Jl sample deposited onto the sample pad at the end of the LFA 
strip, lower than that reported for colloidal-gold LFAs for viruses12–13 or an ELISA for MS2 
virus35. We anticipate that the imaging assay developed here can be integrated with 
inexpensive detection technologies, including paper microfluidics36–37 and smartphone-
based fluorescence imaging,38–39 to enable point-of-care rapid diagnostics for viruses in 
resource-limited settings.
Methods
Culture and titration of MS2 viruses and M13 phage
MS2 virus (ATCC, #15597-B1) and its E. coli host strain (ATCC, #15597) were obtained 
from the American Type Culture Collection (Manassas, VA). AviTag-displaying M13 phage 
(AviTag-M13) were a gift from Prof. Brian Kay at the University of Illinois at Chicago. The 
culturing and titering of MS2 and M13 phage were performed as described in Reference 21.
AlexaFluor 555 labeling of AviTag-M13
AviTag-M13 were modified with AlexaFluor 555 Carboxylic Acid (Succinimidyl Ester, Life 
Technologies #A-20009) as illustrated in Figure 2. This amine-reactive AlexaFluor 555 was 
conjugated to the primary amines of the p8 major coat proteins of AviTag-M13. PEG 
precipitation of AviTag-M13 was performed to replace the buffer in the stock solution with 
0.2 M sodium bicarbonate at pH 8.3 as the optimum reaction buffer for fluorescent labeling. 
For PEG precipitation, 100 μL of 1012 pfu/mL AviTag-M13 was mixed with 20 μL of PEG/
NaCl (20% w/v PEG 8000/2.5 M NaCl), and incubated on ice for 1 h. The PEG solution was 
then centrifuged at 11,000 × g for 20 min at room temperature and the AviTag-M13 pellet 
was resuspended in 100 μL of 0.2 M sodium bicarbonate buffer, pH 8.3. Next, 5 μL of 10 
mg/mL AlexaFluor 555 was added to the AviTag-M13 solution, and the solution was 
incubated overnight at 4°C on a shaker in the dark. To terminate the labeling reaction, 10 μL 
of 1.5 M hydroxylamine at pH 8.5 was added to the AviTag-M13 solution and incubated for 
1 h at room temperature. To remove free Alexa molecules, PEG precipitation and 7 KDa 
molecular weight cut-off ZebaTM spin desalting columns (Thermo Scientific #89877) were 
used. 100 μL of 1012/mL AviTag-FluorM13 were stored in the dark at 4°C until used.
Biotinylation of AviTag-FluorM13
AviTag-M13 phage display a peptide on the p3 tail protein which can serve as a substrate 
for E. coli biotin ligase and is inherently biotinylated at greater than 50% efficiency when 
grown in an E. coli host that contains the pBirA plasmid.40 We completed the biotinylation 
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in vitro using E. coli biotin ligase (birA), according to the manufacturer’s instructions 
(Avidity AviTagTM Technology) or using biotin ligase produced in-house. After incubation 
for 1 h at room temperature in the dark, excess biotinylation reagents were removed from 
the biotinylated FluorM13 (Biotin-FluorM13) solution via PEG precipitation and a 7K 
MWCO ZebaTM spin desalting column.
Neutravidin conjugation of Biotin-FluorM13
100 μL of a 1012 pfu/mL Biotin-FluorM13 solution was mixed with 10 μL of 0.1 mg/mL 
neutravidin (Thermo Fisher Scientific #31000), and the resulting solution was incubated for 
1 h at room temperature in the dark. To remove excess neutravidin, the solution was 
dialyzed for 20 h against 1 liter of PBS using a Float-A-Lyzer 100K MWCO dialysis device 
(Spectra/Por #G235035) with five complete buffer changes during the dialysis.
Biotinylation of anti-MS2 antibodies
Rabbit Anti-MS2 antibodies (Tetracore, #TC-7004-002) were biotinylated using EZ-Link 
Sulfo-NHS-LC Biotin (Thermo Scientific #21335) following the manufacturer’s protocol. In 
brief, 10 μL of 2.8 mg/mL anti-MS2 antibody solution was mixed with 20 μL of 0.1 mg/mL 
EZ-Link Sulfo-NHS-LC Biotin and 90 μL of PBS. The solution was then incubated for 30 
min at room temperature. A 7K MWCO ZebaTM spin desalting column was used to remove 
excess biotin.
Functionalization of FluorM13 with anti-MS2 antibodies through biotin-avidin conjugation
10 μL of 0.23 mg/mL biotinylated anti-MS2 antibodies were mixed with 990 μL of 1.1 × 
1011 pfu/mL neutravidin-functionalized FluorM13 in PBS and incubated for 1 h at room 
temperature in the dark. Excess biotinylated anti-MS2 antibody was removed using a Float-
A-Lyzer 300K MWCO dialysis device with five complete buffer changes during the 
dialysis.
Estimation of the biotin/antibody ratio of biotinylated anti-MS2 antibodies using the HABA 
assay
A HABA assay (Thermo Scientific, #28005) was used to estimate the biotin/antibody ratio 
of biotinylated anti-MS2 antibody (additional details are given in the Supporting 
Information). From the difference between the absorbance of HABA/Avidin solution and 
that of a HABA/Avidin/Biotinylated-anti-MS2 antibody mixture measured at 500 nm, a 
ratio of biotin to anti-MS2 antibody of 3.1 was estimated using the analytical formula 
provided by the manufacturer.
Comparison of the degree of biotinylation of Biotin-FluorM13 using ELISA
The degrees of biotinylation of AviTag-FluorM13 and Biotin-FluorM13 were compared 
using TMB (3,3′,5,5′-Tetramethylbenzidine)-ELISA. Additional details on the ELISA 
protocol can be found in Supporting Information.
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Assessment of anti-MS2 antibody-functionalized FluorM13 using ELISA
We assessed the conjugation of rabbit anti-MS2 antibodies onto FluorM13 using ELISA. 
The ELISA plate was coated with 100 μL of 5 μg/mL anti-rabbit IgG antibody (Sigma-
Aldrich, #R4880) and incubated overnight at 4°C. The plate wells were washed and rinsed 
four times each with PBST and PBS, respectively, and blocked with 300 μL of 2% (w/v) 
BSA in PBS for 2 h at room temperature. 100 μL of rabbit anti-MS2 antibody-functionalized 
FluorM13 at concentrations of 0, 108, 109, and 1010 pfu/mL were added to the wells and 
incubated for 1 h at room temperature; for the negative control experiment, AviTag-
FluorM13 with no antibody was added to the wells. Bound antibody-functionalized 
FluorM13 were allowed to react with 100 μL of HRP-conjugated anti-M13 antibody 
(1:5,000 dilution in 2% (w/v) BSA in PBS) for 1 h at room temperature, followed by 
washing and rinsing. To develop the color, 50 μL of TMB was added to the plate for 10 min, 
after which the reaction was terminated by addition of 50 μL of 2 N H2SO4. Absorbance 
was measured at 450 nm in the ELISA reader.
Modification of magnetic particles with proteins
Carboxylated magnetic particles (1 μm diameter, Thermo Scientific, #4515-2105-050350) 
were coated with anti-M13 antibody, neutravidin, biotinylated-BSA, or anti-rabbit antibody 
using standard 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide·HCl–N-
Hydroxylsuccinimide (EDC-NHS) coupling. To pre-activate magnetic particles for protein 
coupling, we mixed 200 μL of a 5% (w/v) solution of magnetic particles with 230 μL of 50 
mg/mL NHS and 230 μL of 42 mg/mL EDC in 50 mM of MES buffer at pH 6 and diluted to 
1 mL by adding 340 μL of 50 mM MES buffer. The mixture was incubated for 30 min on a 
rotator at room temperature. The particles were washed using a magnetic stand with 50 mM 
of MES buffer once and PBS twice and briefly sonicated after each wash. The magnetic 
particles were then resuspended in 1 mL of PBS. 100 μL of 1% EDC-NHS preactivated 
magnetic particles were mixed with 100 μL of one of the protein solutions (0.56 mg/mL 
anti-MS2 antibody, 1.5 mg/mL neutravidin, 1.5 mg/mL biotinylated-BSA, or 0.5 mg/mL 
anti-rabbit antibody). After 1 h incubation on a rotator at room temperature, magnetic 
particles were washed with PBS three times and briefly sonicated after each wash. For the 
first quenching step, magnetic particles were resuspended in 200 μL of 0.1 M 
hydroxylamine in PBS, and incubated for 1 h on a rotator at room temperature. Magnetic 
particles were washed with PBS three times and resuspended in 200 μL of 2% (w/v) BSA in 
PBS for the second quenching step. After overnight incubation, magnetic particles were 
washed and then resuspended with 200 μL of 0.1 % (w/v) BSA in PBS and 0.005% 
ProClin®300 preservative (SUPELCO, #48126).
Magnetic particle assays for characterization of functionalized FluorM13
10 μL of a solution of protein-functionalized magnetic particles at a concentration of 1.36 × 
108 particles per mL, equal to 0.01% (w/v), was mixed with 50 μL of a solution of 
functionalized FluorM13 at a concentration of 1011 pfu/mL. The mixture was incubated on a 
slow shaker for 1 h at room temperature in the dark and then washed six times with 0.1% 
(v/v) Tween 20 in PBS using a magnetic stand. The particles were then resuspended in 30 
μL PBS. The particle solution was pipetted into a well chamber that was formed by placing a 
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silicon isolator (Grace Bio-Labs, Bend, OR; size: 4.5 mm diameter × 1.7 mm depth) on the 
coverslip. A magnet was put under the coverslip for 10 sec to pull the particles down to the 
coverslip surface. A light microscope (Leica, DMI 3000B) equipped with a 100× oil 
immersion objective lens (NA 1.4) was used to image particles in both fluorescence and 
brightfield modes. To detect AlexaFluor 555 using fluorescence microscopy, samples were 
illuminated with a 120 W mercury lamp through a filter cube consisting of an excitation 
filter (BP 515–560 nm), a dichromatic mirror (580 nm), and a suppression filter (LP 590 
nm). A back-thinned frame transfer CCD camera (Hamamatsu, C9100-12) was used to 
capture images with a 0.3 sec shutter speed. We acquired twenty pairs of brightfield and 
fluorescence micrographs of magnetic particles at the same focal area. Using an automated 
counting program (Figure S1 in Supporting Information), we counted all particles in the 
brightfield micrographs and the bright particles that bore bound FluorM13 in the 
fluorescence micrographs. We examined ~5,000 particles across each set of twenty images 
and calculated the fraction of bright particles by dividing the number of bright particles by 
the total number of particles.
Lateral flow assay
Fusion 5 strips (1 mm × 50 mm × 110 μm, GE Healthcare & Life Sciences #8151-9915) 
were modified with 1 μL of 0.43 mg/mL rabbit anti-M13 antibody and 1 μL of 0.56 mg/mL 
rabbit anti-MS2 antibody in 50 mM acetate buffer at pH 3.6 by hand-spotting at control and 
test lines, respectively. MS2 virus samples were prepared with six time-serial dilutions in 
LFA buffer (10% BSA and 30% glycerol in PBS) at concentrations of 107, 106, 105, 104, 
103, 102, and 0 pfu/mL. In the first step of the assay, 10 μL of each MS2 virus sample was 
dispensed onto the sample pad at one end of an LFA strip. Each strip was washed with 200 
μL of washing buffer (0.1% Tween-20, 0.1% Triton X-100 in PBS). Next, 10 μL of 108 
pfu/mL anti-MS2 antibody-functionalized FluorM13 in LFA buffer was dispensed onto the 
sample pad. Each strip was washed and rinsed with 200 μL of washing buffer and 100 μL of 
PBS, respectively, to remove non-specifically bound M13 reporters. After drying in air for 1 
h, the strips were immersed with pure glycerol to match the refractive index of the Fusion 5 
membrane. FluorM13 reporters bound to strips were imaged using a Leica DMI 3000B 
fluorescence microscope equipped with a 63× oil immersion objective lens (NA 1.4). 
Micrographs were acquired at the test, transition, and control lines using a back-thinned 
frame transfer CCD camera (Hamamatsu, C9100-12) and analyzed using automated image-
processing routines.
Results and Discussion
Characterization of FluorM13 reporter phage
To implement an imaging-based LFA format we developed novel reporter agents, 
fluorescent antibody-functionalized bacteriophage that were able to specifically bind to an 
analyte virus and were readily imaged at the single-reporter level using fluorescence 
microscopy. M13 bacteriophage modified to express the AviTag peptide were first 
fluorescently labeled with AlexaFluor 555 and subsequently conjugated with antibodies to 
MS2, as shown in Figure 2. Individual fluorescently-conjugated phage were readily imaged 
using fluorescence microscopy (Figure 3a). Subsequently, we enzymatically biotinylated the 
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AviTag peptide and confirmed biotinylation using a TMB-ELISA assay. The absorbance of 
biotin-conjugated FluorM13 on a neutravidin-coated plate was higher than that of the 
AviTag FluorM13 prior to conjugation, confirming that the FluorM13 phage were 
successfully biotinylated (Figure 3b). We prepared anti-MS2 antibodies with a ratio of 3.1 
biotins per antibody and confirmed that the anti-MS2 antibodies were retained on the 
FluorM13 phages by ELISA (Figure 3c).
To further verify each of the FluorM13 functionalization steps, we employed a magnetic 
bead assay (Figure 4). We mixed magnetic particles functionalized with a variety of proteins 
with FluorM13 phage bearing biotin, neutravidin, or antibodies to the model virus MS2 and 
counted the fraction of magnetic particles that were fluorescent, signifying binding of the 
phage (additional details are given in the Supporting Information). For each pair of particle 
and phage surface chemistries, the fluorescence signal was consistent with that expected 
from the surface chemistries. In pairs in which specific binding was expected (e.g. between a 
magnetic particle functionalized with antibodies to M13 and any of the FluorM13 phage, 
Figure 4a, b and c) a large fraction of magnetic particles were fluorescent, confirming good 
binding between phage and particles. Conversely, in those cases in which specific binding 
was not expected (e.g. between biotin-functionalized particles and biotin-conjugated 
FluorM13 phage, Figure 4g) few magnetic particles were fluorescent, confirming that the 
phage did not bind non-specifically to the particles. We attributed the affinity of the anti-
MS2 Ab FluorM13 phage for neutravidin-coated magnetic particles (Figure 4f) to the 
presence of excess biotins on the anti-MS2 antibody, which may bind to the neutravidin on 
the particles.
Automated image processing to count individual phage
To efficiently quantify the number of reporter phage bound to the LFA strip, we developed 
and employed an automated algorithm that locates and counts the number of the fluorescent 
phage in fluorescence micrographs (Figure 5; additional details on image processing 
methods are given in Supporting Information). The software enhanced the image contrast 
and increased the ratio of signal to noise, allowing phage to be counted even against a noisy 
or unevenly illuminated background. In addition, the image processing preserved the non-
spherical shape of the FluorM13 phage, which helps to confirm their identity and allows 
their orientation when bound to the strip to be determined.
Imaging-LFA immunodetection of MS2 virus
To demonstrate the efficacy of our assay we chose as the analyte MS2 virus, which often 
serves as a model for viral pathogens. We deposited 10 μL of a solution containing a known 
concentration of MS2 on a sample pad at one end of antibody-functionalized LFA strips. 
Capillary action transported the MS2 viruses through the strip to the test line, where anti-
MS2 antibodies captured them. Anti-MS2 Ab Fluor M13 reporters subsequently transported 
through the strip were captured both by the MS2 viruses bound to the matrix at the test line 
in a sandwich and by anti-M13 antibodies at a downstream control line. The uniformly 
bright micrographs acquired at the control line indicated that many M13 reporters were 
transported through the strip (Figure 6, top row).
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Individual bright spots in micrographs acquired upstream at the test line (Figure 6, bottom 
row) or in a non-functionalized transition region between the test and control lines (Figure 6, 
middle row) corresponded to individual M13 reporters bound to the strip. Resolving 
individual reporters required matching the refractive index of the Fusion 5 strip (n ≈ 1.5) to 
the solvent, here pure glycerol. Without index matching, scattering from the strip limited our 
ability to resolve single phages. The low number of bound phage in the transition area at 
each concentration compared to the test line indicated that non-specific binding did not 
increase with increasing analyte concentration.
To determine the limit of detection of the imaging LFA, we quantified the number of 
reporters bound at the test line and in the transition region using the automated image-
processing program summarized in Figure 5. The average number of bound reporters per 
micrograph acquired at the test line increased with increasing concentration of analyte MS2 
viruses (Figure 7) but at a rate that was significantly less than linear: as the MS2 
concentration was increased from 102 to 107 pfu per 10 μL, the number of bound phage 
increased by a factor of 5. The lack of proportionality between signal and offered analyte 
concentration, also observed in other assays with phage reporters,19, 24 likely arose from 
steric hindrance and the great heterogeneity of the binding sites offered by the LFA matrix. 
The number of bound reporters in the transition area, by contrast, remained constant and 
independent of analyte concentration. The average number of bound reporters at the test and 
transition regions was different at a significance level of p < 0.05 for all analyte 
concentrations tested down to 102 pfu per 10 μL, corresponding to a titer of 104 pfu/mL 
(Table 1 in Supporting Information). Additionally, the 95% confidence intervals for samples 
with nonzero MS2 concentration down to 102 pfu per 10 μL, indicated by the notches in 
Figure 7, did not overlap with that of the zero MS2 concentration at the test line. Using as 
the criterion for the limit of detection the lack of overlap in the 95% confidence intervals of 
the number of bound M13 reporters, these results suggested that this assay could be used to 
detect as few as 102 pfu per 10 μL. An independent replicate of the assay exhibited an 
identical limit of detection (Figure S4 in Supporting Information). We concluded that the 
limit of detection of this assay was ~102 pfu/strip. This LoD was approximately one-
hundred-fold better than that reported for virus LFAs using gold nanoparticles as 
reporters12–13 and that reported for an ELISA35 for MS2.
Conclusions
We report here a lateral flow immunoassay for viruses that employs fluorescently-labeled 
M13 bacteriophage as reporters. This assay relies on the fact that individual filamentous 
phage can be resolved and hence counted using standard fluorescence microscopy. The limit 
of detection for our imaging LFA was significantly better than that of conventional LFAs 
using gold nanoparticles12–13 and that of an ELISA for MS235, due in part to the resolution 
attained by imaging individual reporters bound to single analyte viruses.
We expect that the LoD can be lowered further by reducing nonspecific binding of the 
reporters in the background region and by optimizing the deposition of the test line to 
maximally concentrate the antibodies there. Additionally, we anticipate that tuning the 
chemistry and geometry of the LFA strip may further improve the LoD. An ideal strip for 
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this assay allows easy transport of the reporters to all antibody-functionalized sites and aids 
capture of the reporters; in future work we therefore plan to vary the strip material as well as 
the size and arrangement of the pores therein. Finally, because reporters must be readily 
transported throughout the strip, we surmise that the shape of the reporter phage may affect 
the LoD; to test this idea, we will test the efficacy of functionalized viral nanoparticles of 
varying morphologies as reporters in this assay.
We envision that the imaging-based LFA described here can be integrated with other 
advances in detection to generate a simple and inexpensive diagnostic for viruses that is 
suitable for point-of-care applications. Adapting our LFA into a paper microfluidics format 
has the potential to reduce the number of handling steps and decrease costs, and would thus 
be promising for use in areas with few trained medical workers43. Fluorescence has already 
enabled multiplexed detection in a variety of modified LFAs44 and multiplexed fluorescence 
imaging is easy to implement in our assay format. Similarly, combining our LFA with 
smartphone-based imaging methods39, 45, which have already been used to image individual 
viruses38, would generate a portable diagnostic. Moreover, recent advances in 3-D printing 
have demonstrated smartphone-compatible imaging systems that can magnify at 1,000x (the 
magnification used in this study), and cost less than a dollar for all materials46, compatible 
with point-of-care diagnostics in resource-limited settings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Imaging lateral flow assay with FluorM13 reporters
Anti-M13 and anti-MS2 antibodies were hand-spotted on Fusion 5 strips to generate test and 
control lines, respectively. The MS2 viruses were dispensed onto distal end of strips that 
were then washed in buffer. The FluorM13 reporters were spotted on the strips to sandwich 
MS2 viruses at the test line. Fluorescence micrographs were acquired at the test line, 
transition, and control line and analyzed using automated-image-processing routines to 
count the FluorM13 reporters.
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Figure 2. Modification of AviTag-M13
(a) AviTag-M13 was modified with AlexaFluor 555 on the p8 major coat proteins. (b) 
AviTag peptides of AviTag-FluorM13 were biotinylated on the p3 tail protein in vitro using 
biotin ligase. (c) Neutravidin was conjugated onto biotin of Biotin-FluorM13 phage. (d) 
Biotinylated anti-MS2 antibody was attached to Neutravidin-FluorM13 through biotin-
avidin conjugation.
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Figure 3. Characterization of modified FluorM13 reporters
(a) Fluorescence micrograph of FluorM13, demonstrating the ability to resolve individual 
reporter phage. (b) TMB-ELISA showing absorbance at 450 nm as a function of Biotin-
FluorM13 concentration offered to bind on a streptavidin-coated plate. (c) TMB-ELISA 
showing absorbance at 450 nm as a function of FluorM13 concentration to confirm anti-
MS2 antibody retention on FluorM13. Error bars indicate standard deviations from triplicate 
measurements.
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Figure 4. Characterization of modified FluorM13 reporters using magnetic particles
FluorM13 functionalized with biotin, neutravidin, anti-MS2 antibody were captured by anti-
M13 antibody-magnetic particles (a, b and c). Neutravidin magnetic particles showed high 
binding affinity with Biotin-FluorM13 (d). The affinity between neutravidin-magnetic 
particles and anti-MS2 Ab FluorM13 (f) was ascribed to excess biotins on the biotinylated 
anti-MS2 antibody based on the result of the HABA assay. The third (g, h and i) and fourth 
(j, k and l) rows showed that biotin-FluorM13 undergo successful neutravidin and anti-MS2 
Ab conjugation, respectively. The bar graphs showed the fraction of fluorescence magnetic 
particles bearing bound FluorM13, corresponding to the representative micrographs. Error 
bars were standard deviations from twenty images analyzed for each pair of magnetic 
particles and modified FluorM13. All images were acquired with identical imaging 
conditions (camera gain = 8, camera exposure time = 0.3 sec, 100× objective lens).
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Figure 5. Automated counting of individual FluorM13 reporters
(a) A fluorescence micrograph was acquired at the LFA test line. (b) Histogram 
equalization34 was used to enhance image contrast, allowing FluorM13 reporters to be 
clearly visible. (c) The Beltrami flow algorithm41 was used to reduce and smooth 
background noise and increase the ratio of signal to noise, while preserving the shape of the 
FluorM13 reporters. (d) A rank-leveling algorithm34 was used to remove uneven 
illumination. (e, f) Global and local thresholds34 were used to segment FluorM13 reporters 
from the background. (g) Brightfield micrograph acquired at the same focal area as in (a) of 
the LFA test line. (h) A connected component labeling algorithm42 was used to 
automatically count FluorM13 reporters. The segmented M13 phage reporters were overlaid 
onto the brightfield micrograph. (i) FluorM13 identified by the algorithm were indicated by 
axis-aligned bounding boxes. The scale bar for all images is 10 μm.
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Figure 6. Representative micrographs from imaging LFAs for MS2 virus detection
For each concentration of MS2/strip, two fluorescence micrographs acquired at the control 
(top; saturated white), transition (middle), and test (bottom) lines are shown. Each 
micrograph was of dimension 130 × 130 Jm2 and the area of the antibody spotted onto 
Fusion 5 strips was ~ 1 mm2, so that at most sixty micrographs could be acquired from each 
antibody spot at a two dimensional plane. In the assay, twenty micrographs were acquired at 
the control, transition, and test lines of an LFA strip. We observed high fluorescence 
intensity at the control lines, leading to the bright white images. Although individual 
FluorM13 reporters cannot be distinguished at the control line, the high fluorescence 
intensity showed that sufficient FluorM13 reporters migrate along the length of the strip. 
The number of FluorM13 reporters bound at the test line increased with increasing number 
of MS2 per strip, and remained invariant at the transition area.
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Figure 7. Limit of detection of LFA
Notch boxplot showing the number of FluorM13 reporters per micrograph as a function of 
number of MS2 phage per strip at LFA test line and transition region (located at 5mm 
further downstream from the test line). Strips were loaded with 10 JL MS2 virus solution at 
various concentrations. FluorM13 reporters were counted from twenty micrographs acquired 
for each MS2 virus concentration using an automated counting program. All test lines of 
LFA strips were distinguishable from the corresponding backgrounds at a statistical 
significance level of p < 0.05 using the t-test. The position of the notches indicated the 95% 
confidence interval; notches for images acquired at the test line for each the nonzero MS2 
concentrations did not overlap with that for zero MS2 concentration.
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